CMPX

The past six months have seen volatility in Compass Therapeutics' stock price, largely influenced by clinical trial results. On April 27, 2026, shares plummeted after mixed results from the COMPANION-002 Phase 2/3 study of tovecimig in biliary tract cancer, which led to analyst downgrades and a law firm investigation. On May 5, 2026, the company reported its first-quarter 2026 results, highlighting positive Phase 2/3 data for tovecimig in BTC, its Orphan Drug Designation, and plans for a BLA submission later in 2026. On March 5, 2026, the company reported full 2025 financial results and provided a business update, noting that tovecimig successfully met the primary endpoint of overall response rate in the COMPANION-002 study.